Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"
Retrieved on:
Monday, September 27, 2021
Policy, Review, Chinese Academy of Sciences, Degenerative disease, Expert Committee on Questions of Population and Racial Policy, Senior, Center, Founder, Statistics, Big data, Safety, Biotechnology, Food, Kyowa Hakko Kirin, Health, CEO, Group, Security, FSMP, Disease, Incidence, Cloud computing, Partnership, ICF, WeChat, Daiichi Sankyo, Diagnosis, Treatment, Alibaba Group, WHO, Hope, Platform, Hospital, Patient, Glycerol phenylbutyrate, AI, IOT, NGO, Muhammad Ali Center, Medical device, Pharmaceutical industry
Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.
Key Points:
- Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.
- "The Global Drug Information Platform for Rare Diseases is an effective exploration by multiple parties for the construction of support system for rare diseases.
- The special policy of Boao Lecheng Pilot Zone and Bo'ao Winhealth Rare Disease Medical Center offer hope for patients.
- For more information, please follow "Bo'ao Winhealth Rare Disease Medical Center" on Wechat.